Bedrijfsoverzicht
Esperion Therapeutics, Inc. is a biopharmaceutical entity focused on the development and commercialization of therapeutic agents designed to manage elevated low density lipoprotein cholesterol levels within the United States market. The company operates within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized pharmaceutical solutions rather than mass-market generic drugs. Esperion maintains a market capitalization of $557.28M, generates annual revenue of $403.14M, and employs a workforce of 294 individuals. These financial and operational figures indicate that the company holds a mid-sized position within its niche, possessing significant cash reserves relative to its employee base, which suggests an established operational footprint capable of sustaining research and development activities without immediate need for external capital injection.
Financiële gezondheid
The company reported revenue of $403.14M and an EBITDA of $60.38M for the trailing twelve months, while the net income stood at -$22.682M, revealing a substantial gap where operating profitability is eroded by significant non-operating expenses or losses in other comprehensive income categories. The free cash flow was recorded at -$52.594.876M, indicating that despite generating revenue, the company is currently burning cash, which constrains immediate financial flexibility and necessitates continued access to liquidity sources to fund operations. Marginal analysis shows a gross margin of 56.1%, reflecting a healthy cost of goods sold structure typical for pharmaceutical products, an operating margin of 50.6% that demonstrates effective control over operational expenses, and a profit margin of -5.6% which highlights the current unprofitability at the bottom line despite strong operational efficiency. Balance sheet analysis reveals total cash of $167.85M against total debt of $548.00M, creating a net debt position, while the debt-to-equity ratio is listed as N/A, suggesting a capital structure heavily reliant on equity or where equity is negligible, pointing to a leveraged stance rather than a conservative one. Liquidity is supported by a current ratio of 1.54, indicating that the company holds sufficient current assets to cover its short-term liabilities with a margin of safety. Return on Equity is listed as N/A due to the equity structure, whereas the return on assets stands at 9.3%, revealing that management is generating nearly 10 cents of profit for every dollar of assets employed, which is a positive indicator of asset utilization efficiency despite the net loss.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to the net loss, whereas the forward P/E is 7.40, implying that the market prices the stock based on anticipated future earnings normalization rather than current profitability. The price-to-book ratio is -1.76, a negative figure that indicates the market values the company below its book value, a common characteristic for biotechnology firms where current assets may not fully capture the value of intellectual property and future pipeline potential. Alternative valuation metrics include a price-to-sales ratio of 1.38 and an EV/EBITDA of 15.53, suggesting that investors are willing to pay a premium of roughly 1.4 times sales, which reflects confidence in the commercialization of marketed products like NEXLETOL and NEXLIZET despite the current lack of net income. Price action over the past year shows a 52-week high of $4.18 and a 52-week low of $0.69; without a specific current price provided in the source data, the valuation is assessed strictly through these range parameters which define the maximum and minimum volatility observed. The beta value is 1.17, indicating that the stock's price volatility is 17% higher than the broader market benchmark, suggesting that price movements will be amplified relative to general market fluctuations.
Growth & Income
Revenue growth year-over-year is recorded at an impressive 143.7%, demonstrating a rapid expansion in top-line sales, while earnings growth is listed as N/A due to the current net loss position, implying that revenue expansion is currently outpacing the path to profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings are retained within the business to fund research, development, and working capital needs rather than being distributed to shareholders. This strategy of reinvesting earnings into growth is typical for biopharmaceutical companies in the growth phase where capital expenditure is prioritized over shareholder distributions. The overall growth and income profile is characterized by aggressive revenue expansion and a complete absence of dividend income, focusing entirely on capital appreciation potential through the successful commercialization of its lipid-lowering therapies.